Zacks Research Issues Negative Estimate for JNJ Earnings

Johnson & Johnson (NYSE:JNJ) – Equities research analysts at Zacks Research lowered their Q2 2025 earnings per share (EPS) estimates for Johnson & Johnson in a research note issued to investors on Tuesday, January 7th. Zacks Research analyst K. Shah now expects that the company will post earnings of $2.67 per share for the quarter, down from their previous forecast of $2.68. The consensus estimate for Johnson & Johnson’s current full-year earnings is $9.94 per share. Zacks Research also issued estimates for Johnson & Johnson’s Q3 2025 earnings at $2.68 EPS.

Other analysts have also issued reports about the company. Morgan Stanley lifted their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Royal Bank of Canada raised their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Guggenheim raised their target price on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Finally, Wells Fargo & Company upped their price target on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.71.

Johnson & Johnson Trading Down 2.8 %

NYSE:JNJ opened at $142.10 on Thursday. Johnson & Johnson has a 52 week low of $141.44 and a 52 week high of $168.85. The firm has a 50-day moving average price of $150.03 and a two-hundred day moving average price of $156.04. The firm has a market cap of $342.12 billion, a price-to-earnings ratio of 20.56, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same quarter in the prior year, the business posted $2.66 EPS. The business’s revenue was up 5.2% compared to the same quarter last year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.49%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 71.78%.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds have recently bought and sold shares of the stock. LSV Asset Management lifted its stake in Johnson & Johnson by 39.4% during the second quarter. LSV Asset Management now owns 2,977,570 shares of the company’s stock worth $435,202,000 after purchasing an additional 841,400 shares during the last quarter. Adapt Wealth Advisors LLC boosted its position in Johnson & Johnson by 6.0% during the second quarter. Adapt Wealth Advisors LLC now owns 15,956 shares of the company’s stock valued at $2,332,000 after buying an additional 901 shares during the period. Quest Partners LLC grew its stake in shares of Johnson & Johnson by 13.9% during the second quarter. Quest Partners LLC now owns 12,983 shares of the company’s stock valued at $1,898,000 after buying an additional 1,587 shares during the last quarter. First Foundation Advisors lifted its stake in shares of Johnson & Johnson by 13.2% in the 2nd quarter. First Foundation Advisors now owns 50,940 shares of the company’s stock valued at $7,445,000 after acquiring an additional 5,938 shares during the last quarter. Finally, Private Management Group Inc. boosted its holdings in Johnson & Johnson by 76.5% during the 2nd quarter. Private Management Group Inc. now owns 123,336 shares of the company’s stock valued at $18,027,000 after acquiring an additional 53,452 shares during the period. 69.55% of the stock is currently owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.